Inflammatory responses involving tumor necrosis factor receptor-associated factor 6 contribute to in-stent lesion formation in a stent implantation model of rabbit carotid artery  by Miyahara, Takuya et al.
Inflammatory responses involving tumor necrosis
factor receptor-associated factor 6 contribute to
in-stent lesion formation in a stent implantation
model of rabbit carotid artery
Takuya Miyahara, MD,a,b,c Hiroyuki Koyama, MD,a,b,c Tetsuro Miyata, MD,b Hiroshi Shigematsu, MD,b
Jun-Ichiro Inoue, MD,d Tsuyoshi Takato, MD,c andHirokazu Nagawa, MD,b Tokyo, Japan
Objective: Inflammatory responses are considered to represent a unique property after stent implantation, and we
previously demonstrated that inflammatory signaling involving tumor necrosis factor receptor-associated factor 6
(TRAF6) contributes to neointimal formation in a balloon injury model of rabbit carotid artery. The purpose of this
study was to examine the role of TRAF6 in in-stent lesion formation after stent implantation in the rabbit carotid artery.
Methods: Rabbit carotid arteries were injured with a 2F Fogarty catheter, and 28 days later, the same arteries were
implanted with a 3-mm-diameter Palmaz-Schatz stent. A dominant negative (DN) form of TRAF6 (pME-FLAG-
T6RZ5) was then transferred using a plasmid-based electroporation method. Its effects were evaluated compared with
the findings in arteries treated with control plasmid (pME-FLAG).
Results: Immunostaining with anti-FLAG tag antibody showed that an expression plasmid vector containing the
DN-TRAF6 sequence was successfully transferred to the arterial intima and media. Morphometric analyses revealed that
the increase of intimal area in in-stent lesions was significantly inhibited by DN-TRAF6 14 days after stent implantation
(DN-TRAF6 group, 3.01  0.25  105 m2 vs control group, 4.25  0.23  105 m2, P < .01), and the cell density
was increased compared with that in the control group. In the DN-TRAF6 plasmid-treated vessels, cell replication was
prevented in both the intima and media, and fewer leukocytes adhered to the luminal surface. Moreover, DN-TRAF6
suppressed macrophage infiltration, activation of proteases, and proteoglycan accumulation in the in-stent intima.
Conclusions: These findings suggest that TRAF6 plays an important role in cell replication, inflammatory cell infiltration,
protease activity, and extracellular matrix accumulation that contributes to in-stent lesion development. (J Vasc Surg
2006;43:592-600.)
Clinical Relevance: The purpose of the present study was to determine the role of TRAF6 in in-stent lesion formation
after stent implantation in a rabbit carotid artery. A stent was implanted in an artery with a pre-existing intimal lesion,
and transfer of plasmid containing TRAF6 was performed using an in vivo electroporation method. We believe that this
model mimics the process of in-stent lesion formation in the clinical setting, and this study suggests a possible strategy for
preventing in-stent restenosis.In-stent lesion formation after vascular stent implanta-
tion has been attributed principally to intimal hyperplasia,1
but the mechanism promoting in-stent lesion development
is poorly understood. Stent implantation is considered to
induce intimal hyperplasia through proliferation and mi-
gration of vascular smooth muscle cells (SMCs) and accu-
mulation of extracellular matrix (ECM) in the newly
formed intima.2-5 Monocytes and macrophages have also
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592been associated with neointimal formation after stent im-
plantation.6 A previous study showed that abundant leuko-
cytes adhered to the luminal surface, and significant infiltra-
tion of macrophages was observed after stent implantation in
a rabbit carotid artery7; these findings suggest that inflamma-
tory responses represent a unique property after stenting.
Moreover, we recently reported that inflammatory signal-
ing involving tumor necrosis factor receptor-associated fac-
tor 6 (TRAF6) contributes to neointimal formation in a
balloon injury model of rabbit carotid artery.8 In inflam-
matory signaling pathways such as CD40 signaling, TRAF6
serves as an adaptor protein that links downstream kinase
cascades, which results in activation of transcription factors,
including nuclear factor-B (NFB).9
The purpose of the present study, therefore, was to
determine the role of TRAF6 in in-stent lesion formation
after stent implantation in a rabbit carotid artery. A stent
was implanted in an artery with a pre-existing intimal
lesion, and plasmid transfer was performed by using an
in-vivo electroporation method.10 We believe that this
model mimics the process of in-stent lesion formation in
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egy for preventing in-stent restenosis.
MATERIALS AND METHODS
Plasmid construction. The full coding region of the
DN-TRAF6 gene was isolated from pMX-T6mut-puro by
EcoRI and NotI digestion and then inserted into the expres-
sion plasmid vector, pME-FLAG, between the EcoRI and
XhoI sites to make pME-FLAG-T6RZ5 (DN-TRAF6 plas-
mid). A deletion mutant that lacks the RING finger and zinc
fingers of TRAF6 acts as a dominant negative mutant, since
TRAF6 stimulates both NFB and extracellular signal-
regulated kinase1/2 (ERK1/2) activity through its NH2-
terminal region containing a RING finger and zinc fin-
gers.11,12 The plasmid vector, pME-FLAG, which did not
contain the DN-TRAF6 gene, was used as a control plas-
mid. All these plasmids were grown in Escherichia coli
JM109 and purified by using Plasmid Mega Kits (Qiagen,
Hilden, Germany). In this study, DN-TRAF6 plasmid-
treated vessels (DN-TRAF6 group) were compared with
control plasmid-treated vessels (control group) to examine
the role of TRAF6 after stent implantation.
Stent implantation model and in vivo transfer of
plasmid using electroporation. Male Japanese white rab-
bits (2.5 to 3.0 kg) (Saitama Rabbitry, Saitama, Japan) fed
a normal diet were used in all experiments, and all protocols
were conducted according to the Guide for Animal Experi-
mentation of TheUniversity of Tokyo. Rabbits were anesthe-
tized by an intramuscular injection of xylazine (2.5 mg/kg)
and ketamine (50 mg/kg), and all surgical manipulation
and gene transfer were carried out to only the left carotid
artery, since bilateral neck surgery can result in respiratory
dysfunction. A 2F Fogarty balloon catheter (BaxterHealth-
care Co, Deerfield Park, Ill) was introduced into the left
common carotid artery. The balloon was inflated at 1.5 atm
and passed through the common carotid artery three times
with constant rotation (first injury).
At 28 days after the first injury, plasmid transfer and
stent implantation were performed. After intravenous ad-
ministration of heparin (200 USP U/kg), in vivo electro-
poration was performed as described by Matsumoto et al.10
Plasmid DNA solution at a concentration of 400 g/mL
was instilled into the luminal space of the carotid artery. A
segment 15 to 30 mm from the carotid bifurcation was
stimulated by electronic pulses delivered through an elec-
tronic pulse generator (Electro Square Porator ECM830,
BTX, SanDiego, Calif) using a pair of electrode plates at 30
voltage (20-millisecond pulse length; 10 pulses). The sec-
ond pulse was stimulated with opposite polarity. After
plasmid transfer, a 3-mm-diameter Palmaz-Schatz stent
(spiral articulation type, 17.4 mm long) (Cordis/Johnson
& JohnsonCo,Warren, NJ)mounted coaxially on a 3-mm-
diameter AQUA T3 PTCA dilatation catheter (20 mm
long) (Johnson & Johnson) was passed into the left com-
mon carotid artery. The proximal edge of the stent was
positioned 15 mm from the carotid bifurcation.
Rabbits were killed at 3, 7, and 14 days after stent
implantation (6 animals at each time point in each group)(Fig 1), and one group of rabbits without stent implanta-
tion was killed at 28 days after the first injury as a control.
Ten minutes before death by injection of an overdose of
sodium pentobarbital, rabbits received an injection of
Evans blue (1 mL of a 5% solution) (Sigma, St Louis, Mo)
to mark the de-endothelialized area. Lactated Ringer’s
solution (Otsuka Pharmaceutical Co, Tokyo, Japan) was
infused for 3 minutes at 120mmHg in a retrograde fashion
from the abdominal aorta, and 4% phosphate-buffered para-
formaldehyde was perfused for 5 minutes at 120 mmHg.
The left carotid artery was excised and immersed in
the same fixative for an additional 1 hour. The artery was
opened longitudinally, and four segments of artery were
excised. Segments taken 16 to 18mmand26 to 28mm from
the carotid bifurcation were used for histologic study after
careful removal of the stent under a stereomicroscope, and
segments taken 18 to 20 mm and 20 to 26 mm from the
carotid bifurcation were analyzed by electron microscopy.
Histology and morphometry. DN-TRAF6 or con-
trol plasmid was transferred to the arterial wall at 28 days
after balloon injury, and transfer of plasmid was confirmed
2 days later by using a monoclonal antibody against FLAG
tag (1:100, anti-FLAGM2monoclonal antibody) (Sigma),
which was inserted into these plasmids. In addition, the
time course of plasmid expression was evaluated by immu-
nostaining against FLAG-tag at 3, 7, and 14 days after
transfer (n 3 for each time point). Fixed segments of the
resected artery were embedded in paraffin, 4-m cross-
Fig 1. Experimental protocol. DN-TRAF6, Dominant negative
tumor necrosis factor receptor-associated 6.sections were cut, and a monoclonal antibody against
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trypsin and blocking with 1% normal goat serum. Subse-
quent incubation with biotinylated goat anti-mouse immu-
noglobulin G (1:100) (Vector Laboratories, Burlingame,
Calif) and an ABC Elite kit (Vector) was performed.
Fixed segments of the resected artery (two segments
per animal) were embedded in paraffin, and 4-m cross-
sections were cut and stained with hematoxylin and eosin
for morphometric analyses. The area of the intimal layer
was measured, the total number of nuclei in the intima was
counted as the intimal cell number, and the intimal cell
density was calculated as the ratio of intimal cell number to
intimal area for each slide.13
At 1, 9, and 17 hours before the rabbits were killed,
they were injected subcutaneously with 5-bromo-2=-
deoxyuridine (BrdU) (25mg/kg) (BoehringerMannheim,
Mannheim, Germany) to assess cell replication. Replicating
cells were identified with a monoclonal antibody against
BrdU (Bu 20a) (DAKO, Glostrup, Denmark) and counter-
stained with hematoxylin. The percentage of BrdU-positive
cell number to the total cell number (BrdU labeling index)
in the media or intima was calculated in each section.13
Macrophage infiltration in the media was evaluated by
using a monoclonal antibody against rabbit macrophages
(1:100, RAM11) (DAKO) and counterstaining with hema-
toxylin. The percentage of immunostained cell number to
the total cell number (macrophage index) in the media was
calculated in each section.
Scanning and transmission electron microscopy.
The lumen of the artery was observed using scanning
electron microscopy without removal of the stent struts.
Segments of the artery were fixed overnight in solution of
phosphate-buffered 2.5% glutaraldehyde and 2% parafor-
maldehyde. The opened vessels were prepared as described
previously13 and examined with a Hitachi S-430 (Hitachi
Instruments, Inc, Tokyo, Japan) scanning electron micro-
scope at 20 kV. For transmission electron microscopy, after
removal of the stent struts, some pieces were immersed
overnight in sodium acetate-buffered 2.5% glutaraldehyde
and 0.2% Cupromeronic blue (Sigma) with 0.3 mol/L
magnesium chloride.14 Thin sections were mounted on
copper grids and examined with an Hitachi H-7000 trans-
mission electron microscope at 75 kV.
Zymography. Other rabbits were killed at 3, 7, and 14
days after stent implantation (3 to 4 animals for each time
point in each group in addition to the 6 animals that were
perfusion-fixed) as described above, and one group of
rabbits without stent implantation was killed at 28 days
after the first injury as control. The rabbits received an
injection of Evans blue before sacrifice, and then the carotid
artery was resected and separated into intimal and medial
tissue under a stereomicroscope. Resected specimens were
pooled and pulverized under liquid nitrogen, and lysates
were prepared as described previously.15
Equal amounts (10g total protein) of each lysate were
separated on 8% sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) to detect plasminogen activa-
tor activity.15 Substrate gels consisted of a mixture of 1.25%agar, 2% nonfat milk, and 40 g/mL plasminogen from
human plasma (Calbiochem, San Diego, Calif) in 100
mmol/L Tris (pH 8.1) on a flat glass. These zymograms
were allowed to develop at 37°C for 24 hours, and photo-
graphs were taken using dark-ground illumination.
The same lysate of each sample was applied to 8%
SDS-PAGE copolymerized with 0.1% gelatin (Sigma) as a
substrate to evaluate the gelatinolytic activity of matrix
metalloproteinases.16 The gels were stained with Coomas-
sie stain (Coomassie Brilliant Blue R-250, Bio-Rad Labo-
ratories, Hercules, Calif) for 30 minutes, destained in
destaining solution (Bio-Rad), and photographed.
Statistics. Values are shown as mean  SEM. To
evaluate morphometric data, the BrdU index, and the
macrophage index, the mean of each value from two ca-
rotid segments per animal was calculated for statistical
analysis. Analysis of variance followed by Fisher’s protected
least significant difference test was used for analysis of the
time course of morphometric data. Kruskal-Wallis test fol-
lowed by Scheffe’s F test was used for analysis of the time
course of the BrdU index and macrophage index. Differ-
ences between the DN-TRAF6 group and control group
were evaluated by unpaired Student’s t test and adjusted for
multiple comparison by the Bonferroni correction. All data
were considered significant at P  .05.
RESULTS
Plasmid transfer. Immunohistochemical staining with
anti-FLAG tag antibody showed that an expression plasmid
vector containing the DN-TRAF6 sequence or control
plasmid was successfully and equally transferred to both the
intima and media at 2 days after transfer (Fig 2, A and B).
The expression was maintained at the same level on day 3,
had decreased on day 7, and had almost disappeared on day
14 (Fig 2, C, D, and E).
Histologic morphometry. By infusion of Evans blue,
most of the left carotid lumen was stained blue up to day
14, completely including the part with stent implantation.
The biologic effects seemed to match the area of plasmid
treatment. The intimal area was significantly increased from
7 days after stent implantation and continued to widen
until day 14. The increase in intimal area in theDN-TRAF6
group was significantly suppressed compared with that in
the control group; on day 14, the TRAF6 DN group was
at 3.01  0.25  105 m2 vs the control group at
4.25  0.23  105 m2 (P  .01) (Fig 3, A, B, and C).
The intimal cell number was increased from 7 days after
stent implantation in the control group, and the increase of
intimal cells in the DN-TRAF6 group was also inhibited
(Fig 3, D). Although there was a trend toward higher cell
density in the DN-TRAF6 DN group, no significant differ-
ence was observed between the two groups (Fig 3, E).
Cell replication in intima and media. Intimal and
medial cell replication was maximal on day 3 and decreased
gradually thereafter. Compared with the control group, the
intimal BrdU index was significantly lower in the DN-
TRAF6 group from day 3 to 14 (Fig 4, A, B, and C) . The
medial BrdU index was also significantly lower in the
stent implantation.
M, media. Arrowhead, internal elastic lamina. Bar  100 m.
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(Fig 4, D).
Macrophage infiltration in the intima. Immuno-
staining with antimacrophage antibody (RAM11) revealed
the distribution of macrophages in the intima. RAM11-
positive cells were predominantly located around the stent™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
Fig 3. Photomicrographs of (A) control plasmid-treated vessel and
(B) dominant negative tumor necrosis factor receptor-associated 6
(DN-TRAF6) plasmid-treated vessel at 14 days after stent implan-
tation. Sections were stained with hematoxylin and eosin. L, Lu-
men; I (bar with arrows), intima; M, media. *Strut hole; arrow-
head, internal elastic lamina. Bar  100 m. C, Time course of
intimal area. D, intimal cell number. E, intimal cell density in
intima of control plasmid-treated vessel (open bars) and DN-
TRAF6 plasmid-treated vessel (solid bars). Control values (hatched
bars) are from rabbits 28 days after first injury without stent
implantation. Values are shown as mean SEM. (*P .01, **P
.05 vs control without stent implantation, #P  .01, §P  .05
control group vs DN-TRAF6 group). C, Control; d, days afterFig 2. Photomicrographs of (A) control plasmid-treated vessel
stained with anti-FLAG tag antibody, (B to E) dominant negative
tumor necrosis factor receptor-associated 6 (DN-TRAF6) plasmid-
treated vessel stained with anti-FLAG tag antibody, (F) control
plasmid-treated vessel stained with nonspecific immunoglobulin G
(IgG), (G) DN-TRAF6 plasmid-treated vessel stained with non-
specific IgG, and (H) control vessel in which phosphate-buffered
saline was instilled into the luminal space followed by electropora-
tion and stained with anti-FLAG tag antibody. Electroporation
was performed at 28 days after the first injury, and the carotid
artery was resected at 2 days (A, B, and F toH); 3 days (C); 7 days
(D); and 14 days (E) after gene transfer. Sections were stained with
anti-FLAG tag antibody or nonspecific IgG and counterstained
with hematoxylin. L, Lumen; I (bar with arrows), intima;struts and in the mid-intima between the stent struts (Fig 5,
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infiltration was significantly inhibited in the DN-TRAF6
group compared with that in the control group (Fig 5, C).
Leukocyte adhesion to luminal surface. Scanning
electron microscopy showed that the carotid lumen was
predominantly covered with platelets and leukocytes after
stent implantation in the control group. Leukocytes ad-
hered to the luminal surface, especially along the stent
struts, and the distribution was diffuse. Abundant leuko-
cytes were attached to the luminal surface from day 3 to 14.
In contrast, fewer leukocytes were attached to the surface in
the DN-TRAF6 group compared with that in the control
group (Fig 6, A and B).
Extracellular matrix of arterial wall. Transmission
electron microscopy showed collagen fibrils with a distinc-
tive banding pattern, and proteoglycans was stained with
Cupromeronic blue. In the ECM of the DN-TRAF6
group, proteoglycans was scarcely observed compared with
that in the control group, and this finding was observed
especially on day 14 (Fig 6, C and D).
Plasminogen activator activity. The plasminogen ac-
tivator zymogram showed an increase of 54 kDa activity in
both the intima and media after stent implantation. In the
control group, 54 kDa activity in the intima was prolonged
until day 14, and the activity in the DN-TRAF6 group was
suppressed compared with that in the control group at all
time points (Fig 7, A). Similar findings were also observed
in the media (Fig 7, B). The 54 kDa activity represents
urokinase plasminogen activator activity.7
Gelatinolytic activity. In the control group, gelatino-
lytic activity of 72 kDa was observed in both the intima and
media. At 3 days after stent implantation, two extra bands
of 62 kDa and 95 kDa appeared in both layers. The 95 kDa
activity was detected until day 14 in both layers of the
control group, whereas the bands were suppressed on day 3
and 7 and had disappeared by day 14 in the DN-TRAF6
group (Fig 8, A and B). Gelatinolytic activity at 62 and 72
kDa represents the active and latent forms of matrix metal-
loproteinase-2, respectively, and activity at 95 kDa repre-
sents matrix metalloproteinase 9 activity.7
DISCUSSION
Because stent implantation is considered to neutralize
geometric effects, including elastic recoil and remodel-
ing,17 in-stent restenosis has been attributed mainly to
SMC proliferation, migration, and ECM accumulation.2-5
Previous studies showed that the application of intravascu-
lar radiation prevented in-stent lesion development in a
variety of animal models because proliferating cells possess
enhanced sensitivity to ionizing radiation.18,19 Sousa et al20
presented a clinical study in which sirolimus-coated stents
were used for coronary artery stenosis and reported favor-
able results. This finding suggested that cell replication is
also important in human in-stent lesion formation because
sirolimus is an antimitogenic drug and inhibits vascular
SMC replication by several mechanisms.21,22
A previous study from our laboratory showed that
inflammatory responses represent a unique property afterstent implantation in the rabbit carotid artery,7 and Kor-
nowski et al23 reported similar findings in a porcine coro-
nary restenosis model. Moreover, we recently demonstrated
that TRAF6, an important component of inflammatory sig-
naling, contributed to neointimal formation in a rabbit carotid
artery balloon injury model.8 Transfer of DN-TRAF6 to
Fig 4. Photomicrographs of (A) control plasmid-treated vessel and
(B) dominant negative tumor necrosis factor receptor-associated 6
(DN-TRAF6) plasmid-treated vessel at 7 days after stent implan-
tation. Sections were stained with anti-5-bromo-2=-deoxyuridine
(BrdU) antibody and counterstained with hematoxylin. BrdU-
positive cells stain brown. L, Lumen; I (bar with arrows), intima;
M, media. *Strut hole; arrowhead, internal elastic lamina. Bar 
100 m. C, Time course of intimal BrdU index. D, medial BrdU
index in intima of control plasmid treated-vessel (open bars) and
DN-TRAF6 plasmid-treated vessel (solid bars). Control values
(hatched bars) are from rabbits 28 days after first injury without
stent implantation. Values are shown asmean SEM. (*P .01 vs
control without stent implantation, #P  .01 control group vs
DN-TRAF6 group). C, Control; d, days after stent implantation.arterial wall cells significantly blocked NFB activity evalu-
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cell replication, cell migration, and recruitment of macro-
phages, which possibly resulted in significant suppression of
intimal lesion formation. In inflammatory signal pathways
such as CD40 signaling, TRAF6 serves as an adaptor pro-
tein that links cell surface receptors and downstream kinase
cascades, which results in activation of transcription factors,
including NFB.9
NFB plays a crucial role in the activation of cytokine
and adhesion molecule genes involved in atherosclerosis
and lesion development after vascular injury.24 Several in
vivo studies have demonstrated that NFB activation is
significantly involved in neointimal hyperplasia after bal-
loon injury in the rat carotid artery.25,26 TRAF6 is t h e only
TRAF family member that participates in signal trans-
duction of both the tumor necrosis factor receptor
superfamily and the interleukin-1/Toll-like receptor
Fig 5. Photomicrographs of (A) control plasmid-treated vessel and
(B) dominant negative tumor necrosis factor receptor-associated 6
(DN-TRAF6) plasmid-treated vessel at 7 days after stent implan-
tation. Sections were stained with antimacrophage antibody
(RAM11) and counterstained with hematoxylin. Macrophages
stain brown. L, Lumen; I (bar with arrows), intima; M, media.
*Strut hole; arrowhead, internal elastic lamina. Bar  100 m. C,
Time course of macrophage index in intima of control plasmid-
treated vessel (open bars) and DN-TRAF6 plasmid-treated vessel
(solid bars). Control value (hatched bar) is from rabbits 28 days
after first injury without stent implantation. Values are shown as
mean  SEM. (*P  .01, **P  .05 vs control without stent
implantation, #P  .01 control group vs DN-TRAF6 group). C,
Control; d, days after stent implantation.(TLR) superfamily,27,28 and TLR4 has also been shown tobe involved in neointimal formation.29 Accordingly, these
findings suggest that TRAF6 plays a crucial role in in-stent
lesion formation, and the TRAF6-mediated signal pathway
could be a potent therapeutic target in the treatment of
in-stent restenosis.
We transferred DN-TRAF6 by using plasmid-based
electroporation, and sufficient expression was confirmed at
2 days after transfer. The expression was decreased at 7 days
and had almost disappeared at 14 days. These results are
consistent with the previous study by Matsumoto et al.10 In
this study, we evaluated the responses of rabbit carotid
artery with a pre-existing intimal lesion after stent implan-
tation. There were significant differences in both intimal
area and intimal cell number between the DN-TRAF6 and
control groups, indicating that in-stent lesion formation
was inhibited by DN-TRAF6. Further, evaluation of cell
replication by using the BrdU-labeling index demonstrated
that not only medial cell replication but also intimal cell
replication was suppressed. These findings suggest that
inhibition of intimal cell replication by DN-TRAF6 pre-
vented in-stent lesion formation.
Intimal cell replication plays a critical role in lesion
development after stent implantation, since a previous
study demonstrated that intimal cell replication was mark-
edly activated after stent implantation compared with that
after balloon dilatation in the rabbit carotid artery,7 and a
histologic study that used human atherectomy specimens
Fig 6. Scanning electron microscopic view of carotid lumen 3
days after stent implantation in (A) control group and (B) domi-
nant negative tumor necrosis factor receptor-associated 6 (DN-
TRAF6) group. Bar  100 m. Fewer leukocytes adhered to the
luminal surface in the DN-TRAF6 group compared with the
control group. Transmission electron microscopic view of carotid
artery 14 days after stent implantation in (C) control group and
(D) DN-TRAF6 group. Bar  1 m. Proteoglycan accumulation
was suppressed in the DN-TRAF6 group compared with the
control group. Samples were stained with 0.2% Cupromeronic
blue with 0.3 mol/L magnesium chloride. Arrowhead indicates
proteoglycans. C, Collagen.with in-stent restenosis showed ongoing cell replication
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cation, there is a possibility that DN-TRAF6 induced apo-
ptosis of intimal cells and then suppressed lesion formation.
Although we are not able to report findings on apoptosis in
the present study, our previous study showed that transfer
of DN-TRAF6 to an injured artery significantly decreased
apoptosis in the media.8
In the present study, adhesion of leukocytes to the lumi-
nal surface and an increase of macrophages in the in-stent
intima were prevented by DN-TRAF6. These results suggest
that inflammatory responses are a significant feature after
stent implantation. In the control group, leukocyte adhe-
sion was observed immediately after stent implantation,
and abundant leukocytes were detected until day 14. The
time course of leukocyte adhesion was similar to that of
intimal cell replication after stent implantation, suggesting
that leukocytes on the luminal surface play a role in stimu-
lating intimal cells. Inoue et al7 reported similar findings of
prolonged adhesion of leukocytes to the luminal surface
and an increase of macrophages in the intima after stent
implantation in the rabbit carotid artery.
It is of interest that macrophage infiltration increased
gradually until 14 days after stent implantation in the
control group, while DN-TRAF6 inhibited macrophage
infiltration. In the control group, macrophages weremainly
located around the stent struts and in the mid-intima
between the stent struts, and the time course of macro-
phage infiltration was different from that of cell replication
Fig 7. Plasminogen activator zymograms developed for 24 hours
show time course of PA activity in (A) intima and (B) media.
Plasminogen activator activity at 54 kDa was suppressed in the
dominant negative tumor necrosis factor receptor-associated 6
(DN-TRAF6) group compared with that in the control group in
both the intima and media. N, Normal carotid; d, days after stent
implantation.evaluated by the BrdU labeling index, indicating that mac-rophages are not critical for intimal cell replication after
stent implantation.
Suppression of macrophage infiltration resulted in in-
hibition of intimal lesion formation, however. One possible
explanation for this result is that DN-TRAF6 prevented
in-stent lesion formation by inhibiting cell migration from
the media to the intima after stent implantation associated
with macrophage infiltration. Several studies that used ar-
terial injurymodels showed that infiltratingmacrophages in
the intima possibly promote an increase of intimal size.31,32
In the present study, suppression of macrophage infiltra-
tion was likely to have caused inhibition of cell migration
through downregulation of proteases, including plasmino-
gen activator and matrix metalloproteinases, since cell
movement in the arterial wall is linked to activation of some
proteases,33,34 and macrophages potentially secrete various
proteases.35,36 Indeed, the activity of both urokinase plas-
minogen activator and matrix metalloproteinase 9 was sup-
pressed in the DN-TRAF6 plasmid-treated vessel, support-
ing the above speculation.
Another interesting finding of the present study is that
intimal cell density was increased after stent implantation,
and there was poor accumulation of proteoglycans in the
ECMof intimal lesions in theDN-TRAF6 group compared
with that in the control group. Although it was also con-
sidered that DN-TRAF6 inhibited ECM accumulation in
in-stent lesions, there was no significant difference in cell
Fig 8. Gelatin zymograms show time course of gelatinolytic ac-
tivity in the (A) intima and (B) media. Matrix metalloproteinase
activity at 95 kDa was suppressed in the dominant negative tumor
necrosis factor receptor-associated 6 (DN-TRAF6) group com-
pared with that in the control group in both the intima and media.
N, Normal carotid; d, days after stent implantation.density up to 14 days between the two groups. One expla-
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accelerated about 2 or 3 weeks after vascular injury.5
A previous study demonstrated that the ECM of intimal
lesions changed to become proteoglycan-rich after stent im-
plantation compared with balloon dilatation.7 These data
suggest that proteoglycans have some roles during in-stent
lesion development. Although it is poorly understood how
the expression and accumulation of ECM molecules are
regulated after stent implantation, various studies showed
that the contents of ECM, such as collagen, elastin, and
proteoglycans, were upregulated after arterial injury,5,14,37
and accumulation of ECM was enhanced after stent im-
plantation.38,39 We speculate that proteoglycan accumula-
tion was promoted by infiltratedmacrophages, since several
in vitro studies showed that some humoral factors released
from macrophages could stimulate other cells to secrete
proteoglycans and macrophages themselves could secrete
some proteoglycans.35,40
The present study has two limitations. The first is that
we observed the early response after stent deployment.
Because expression of the transferred gene had disappeared
by 14 days after transfer, the drug effect might be lost at
later times. Long-term follow-up with long-lasting gene ex-
pressionwill provide further evidence regarding in-stent reste-
nosis. Another limitation is that electroporation-mediated
gene transfer is preferably applied to an exposed artery. This
gene transfer method may be useful for investigative work
but would appear to have little clinical relevance.
CONCLUSION
The present study demonstrated that DN-TRAF6 in-
hibited intimal cell replication, macrophage infiltration,
and proteoglycan accumulation, resulting in the prevention
of in-stent lesion formation. Inflammatory responses in-
volving TRAF6 are considered to have an important role
in in-stent intimal hyperplasia because DN-TRAF6 sup-
pressed leukocyte adhesion to the luminal surface and macro-
phage infiltration into the in-stent intima. Although the
present study clarified only a part of the mechanisms of action
of TRAF6, these data might provide a possible strategy for
preventing in-stent restenosis in clinical practice.
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